WHITEHOUSE STATION, NJ, USA I October 24, 2013 I Merck (MRK), known as MSD outside the United States and Canada, today provided an overview of the clinical trial program for V503, the company’s investigational 9-valent human papillomavirus (HPV) vaccine, to the Advisory Committee on Immunization Practices in the United States. Merck said that the pivotal efficacy trial is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V503 to the U.S. Food and Drug Administration in 2013.
The study evaluated the efficacy, immunogenicity and safety of V503 in females 16-26 years of age. Merck plans to present results from this study, as well as other results from the Phase III clinical program for V503, at the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) congress in November.
About Merck
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.
SOURCE: Merck
Post Views: 315
WHITEHOUSE STATION, NJ, USA I October 24, 2013 I Merck (MRK), known as MSD outside the United States and Canada, today provided an overview of the clinical trial program for V503, the company’s investigational 9-valent human papillomavirus (HPV) vaccine, to the Advisory Committee on Immunization Practices in the United States. Merck said that the pivotal efficacy trial is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V503 to the U.S. Food and Drug Administration in 2013.
The study evaluated the efficacy, immunogenicity and safety of V503 in females 16-26 years of age. Merck plans to present results from this study, as well as other results from the Phase III clinical program for V503, at the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) congress in November.
About Merck
Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.
SOURCE: Merck
Post Views: 315
